Silexion Therapeutics CORP 8-K filings

Silexion Therapeutics is collaborating with Evonik to develop an advanced siRNA formulation for cancer treatment, leveraging Evonik's expertise in long-acting microparticle technology.

Silexion Therapeutics has successfully regained compliance with Nasdaq's minimum bid price and audit committee requirements, resolving previous deficiencies.

Silexion Therapeutics has appointed Professor Amnon Peled as an independent director to its board, filling a vacancy and resolving a Nasdaq listing deficiency related to audit committee composition.

Silexion Therapeutics has completed a 1-for-9 reverse stock split and adjusted its warrants, effective November 29, 2024.

Silexion Therapeutics is progressing its lead candidate, SIL-204, for pancreatic cancer treatment, building on promising Phase 2 trial results showing a significant improvement in overall survival.

Silexion Therapeutics received multiple deficiency notices from Nasdaq regarding minimum market value and audit committee composition, and announced a 1-for-9 reverse stock split to regain compliance.

Silexion Therapeutics Corp shareholders have approved a 1-for-9 reverse stock split at a reconvened extraordinary general meeting.

Silexion Therapeutics announced its Q3 2024 financial results, highlighting progress in clinical and preclinical programs and the completion of its Nasdaq listing.

Silexion Therapeutics Corp has received a notice from Nasdaq for failing to maintain the minimum $1.00 share price, putting its listing at risk.

Silexion Therapeutics reports significant improvements in stability, efficacy, and KRAS targeting range for its next-generation siRNA candidate, SIL-204, in preclinical studies.

Silexion Therapeutics reports a 56% objective response rate in a Phase 2 trial for its pancreatic cancer treatment, LODER, with a 67% resectability improvement in some patients.

Silexion Therapeutics Corp announces the immediate resignation of independent director Ilan Shiloah due to competing time demands.

Silexion Therapeutics is developing a novel RNAi therapy, SIL-204, for KRAS-driven cancers, building on positive Phase 2 trial results showing a 9.3-month overall survival improvement in pancreatic cancer patients.

Silexion Therapeutics Corp, formerly Biomotion Sciences, and Moringa Acquisition Corp have finalized their business combination, with the combined entity's shares and warrants set to trade on Nasdaq under the symbols SLXN and SLXNW, respectively, starting August 16, 2024.